NCT05376878View on ClinicalTrials.gov

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

PHASE4RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

February 25, 2026

Study Completion Date

February 25, 2026

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the Brain
Interventions
OTHER

Copper Cu 64-DOTA-Trastuzumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

DEVICE

Positron Emission Tomography

Undergo PET/MRI

BIOLOGICAL

Trastuzumab

Given IV

BIOLOGICAL

Trastuzumab Deruxtecan

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER